Navigation Links
Agendia Appoints New CEO and Supervisory Board Member

IRVINE, California and AMSTERDAM, October 24, 2011 /PRNewswire/ --

Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer. This follows the resignation of the company's co-founder and chief executive officer, Dr. Bernhard Sixt. Dr. Sixt will remain with the company in an advisory capacity. Agendia also announced the addition of Dr. Colin Goddard, executive chairman and acting CEO of privately held biotechnology firm Coferon, Inc., to its supervisory board of directors.

"On behalf of Agendia's board and all its employees, I would like to personally extend my deepest gratitude to Dr. Sixt for his leadership in making this company an internationally recognized innovator in the molecular diagnostic space," said Hessel Lindenbergh, chairman of Agendia's supervisory board. "David Macdonald is an accomplished leader in our industry and I have no doubt that under his leadership, Agendia will continue to thrive."

Macdonald has served as Agendia's COO since April 2010 and brings with him more than 25 years of international experience developing and commercializing clinical diagnostics and laboratory services for companies including Nova Biomedical, Behring Diagnostics, Nichols Institute and Quest Diagnostics. He has held CEO and COO roles for the past 18 years. He holds a Bachelor of Science degree from Northeastern University in management and finance as well as an MBA from Babson College.

Dr. Goddard served as CEO of OSI Pharmaceuticals, Inc. and as a member of the company's board of directors until it's $4 billion acquisition by Astellas Pharmaceuticals, Inc. in July of 2010. He currently serves as executive chairman and acting CEO of Coferon, Inc., a privately held biotechnology platform company. He is also a director of biotechnology companies PanOptica and Human Genome Sciences, Inc. Dr. Goddard is actively involved as an advisor to several venture capital firms and other industry groups.

"I'm pleased to welcome Collin Goddard to our supervisory board of directors. He brings with him a wealth of knowledge in the biotechnology sector and will be an asset to Agendia moving forward," said Lindenbergh.

About Agendia:

Agendia is an international molecular diagnostic company, focused on the discovery and development of tools to improve the quality of life for cancer patients, by providing healthcare professionals with critical information that enables personalized treatment.   Agendia's Symphony™ suite of breast cancer products is based on genomic analysis of an individual patient's tumor biology, providing unprecedented insight for complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods. For additional information, please visit

SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Launches TargetPrint(R) for Breast Cancer Patients
2. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
3. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
4. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
5. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
6. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
7. /C O R R E C T I O N -- Agendia B.V./
8. FDA Broadens Clearance for Agendias MammaPrint(R)
9. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
10. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
11. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... PRMA Plastic ... November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , ... wake up every day excited to rebuild lives and it’s an honor to have ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
Breaking Medicine News(10 mins):